These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19152219)

  • 1. CYP2C9 polymorphisms: considerations in NSAID therapy.
    Ali ZK; Kim RJ; Ysla FM
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):108-14. PubMed ID: 19152219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical consequences of cytochrome P450 2C9 polymorphisms.
    Kirchheiner J; Brockmöller J
    Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
    Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
    Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
    Zhou SF; Zhou ZW; Huang M
    Toxicology; 2010 Dec; 278(2):165-88. PubMed ID: 19715737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.
    Ma J; Yang XY; Qiao L; Liang LQ; Chen MH
    J Dig Dis; 2008 May; 9(2):79-83. PubMed ID: 18419640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
    Perini JA; Vianna-Jorge R; Brogliato AR; Suarez-Kurtz G
    Clin Pharmacol Ther; 2005 Oct; 78(4):362-9. PubMed ID: 16198655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis.
    Sano E; Li W; Yuki H; Liu X; Furihata T; Kobayashi K; Chiba K; Neya S; Hoshino T
    J Comput Chem; 2010 Nov; 31(15):2746-58. PubMed ID: 20839301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.
    Blanco G; Martínez C; Ladero JM; Garcia-Martin E; Taxonera C; Gamito FG; Diaz-Rubio M; Agundez JA
    Pharmacogenet Genomics; 2008 Jan; 18(1):37-43. PubMed ID: 18216720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding.
    Agúndez JA; Martínez C; García-Martín E; Ladero JM
    Gastroenterology; 2007 Dec; 133(6):2071-2; author reply 2072-3. PubMed ID: 18054585
    [No Abstract]   [Full Text] [Related]  

  • 12. CYP2C9 genotype as a predictor of drug disposition in humans.
    Lee CR
    Methods Find Exp Clin Pharmacol; 2004; 26(6):463-72. PubMed ID: 15349140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype.
    Siemes C; Eijgelsheim M; Dieleman JP; van Schaik RH; Uitterlinden AG; van Duijn CM; Hofman A; Coebergh JW; Stricker BH; Visser LE
    Neth J Med; 2009 Apr; 67(4):134-41. PubMed ID: 19581657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.
    Bae JW; Kim JH; Choi CI; Kim MJ; Kim HJ; Byun SA; Chang YS; Jang CG; Park YS; Lee SY
    Arch Pharm Res; 2009 Feb; 32(2):269-73. PubMed ID: 19280158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.
    Martínez C; Blanco G; Ladero JM; García-Martín E; Taxonera C; Gamito FG; Diaz-Rubio M; Agúndez JA
    Br J Pharmacol; 2004 Jan; 141(2):205-8. PubMed ID: 14707031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic Vivid substrates.
    Marks BD; Thompson DV; Goossens TA; Trubetskoy OV
    J Biomol Screen; 2004 Aug; 9(5):439-49. PubMed ID: 15296644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions.
    Zi J; Liu D; Ma P; Huang H; Zhu J; Wei D; Yang J; Chen C
    Drug Metab Pharmacokinet; 2010; 25(4):343-50. PubMed ID: 20814155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery.
    Beinema MJ; de Jong PH; Salden HJ; van Wijnen M; van der Meer J; Brouwers JR
    Mol Diagn Ther; 2007; 11(2):123-8. PubMed ID: 17397249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2C9 genotype on pharmacokinetics: are all NSAIDs the same?
    van Oijen MG; Laheij RJ
    Gastroenterology; 2007 Dec; 133(6):2073-4; author reply 2074-5. PubMed ID: 18054587
    [No Abstract]   [Full Text] [Related]  

  • 20. Pain control: non-steroidal anti-inflammatory agents.
    Jacqz-Aigrain E; Anderson BJ
    Semin Fetal Neonatal Med; 2006 Aug; 11(4):251-9. PubMed ID: 16679073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.